Imfinzi, Lynparza Plus Neoadjuvant Chemo Improves Response in HER2-Negative Breast Cancer

NEW YORK – The combination of the checkpoint inhibitor durvalumab (AstraZeneca's Imfinzi), the PARP inhibitor olaparib (AstraZeneca/Merck's Lynparza), and standard-of-care neoadjuvant chemotherapy improved pathologic complete response in women with stage II/III HER2-negative breast cancer compared to chemotherapy alone, according to data presented at a major cancer research conference.